Search General Info
Search Education
Search Partnering Companies

Abraham Heifets, PhD

San Francisco, California, United States
Dr. Abraham Heifets is CEO and Co-Founder of Atomwise, where he and Co-Founder Dr. Izhar Wallach invented the use of deep convolutional neural networks for drug discovery.

Dr. Heifets was a Massey Fellow at the University of Toronto—a center for AI innovation—and a Fellow of the Ontario Brain Institute. His doctoral work applied machine learning and classical AI techniques to organic synthesis planning, a long-standing challenge in chemistry. His vision for the future of AI bringing better, safer and more potent drugs to patients was recently featured in the July 2019 Moonshot issue of Newsweek.

Dr. Heifets is a thought-leader on the use of AI for drug discovery and is an author on 24 papers, patents and patent applications. Dr. Heifets has presented his work to the U.S. GAO, the National Institutes of Health, the American Chemical Society, and the Association for the Advancement of Artificial Intelligence.
Speaking In
[Available On-Demand]
Atomwise Inc. invented the first deep learning AI technology for structure-based small molecule…
[Available On-Demand]
The shortcomings of animal disease models are well known. More than 90% of drugs fail in early…